Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

Pharvaris announced that Phase 3 RAPIDe-3 trial results for deucrictibant IR, an oral bradykinin B2 receptor antagonist for on-demand treatment of hereditary angioedema (HAE) attacks, were published in The Lancet. The drug achieved symptom relief in 1.28 hours and complete resolution in 11.95 hours, met its primary endpoint and all 11 secondary endpoints, and showed a well-tolerated safety profile. An NDA with the FDA (PDUFA target date April 23, 2027) and MAA with the EMA are currently under regulatory review.